-+ 0.00%
-+ 0.00%
-+ 0.00%

Evaxion to Present Phase 2 Biomarker Data for Cancer Vaccine EVX-01 at SITC 2026

PUBT·11/03/2026 14:02:07
Listen to the news
Evaxion to Present Phase 2 Biomarker Data for Cancer Vaccine EVX-01 at SITC 2026
  • Evaxion will present new phase 2 data on personalized cancer vaccine EVX-01 at SITC in Phoenix on Nov. 6-7, 2026.
  • The vaccine combined with pembrolizumab induced cancer-targeting immune responses and broader immune changes in patients with advanced melanoma.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evaxion A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611030900OMX_____CNEWS_EN_GNW1001301514_en) on November 03, 2026, and is solely responsible for the information contained therein.